S.3 Ep. 6 | Beyond the Headlines

AHA 2026 and Science's Last Mile

Streaming now on: Amazon Music  |  Apple Podcasts  |  Spotify  |  Soundcloud  |  YouTube

Learn More About Beyond the Endpoint  |  View All Episodes


In this special Beyond the Headlines episode, hosts Emily O'Brien, Manesh Patel, and Daniel Edmonston look past the press releases from the 2026 American Heart Association (AHA) Scientific Sessions in Chicago. They open with a behind-the-scenes look at Patel's view of the meeting as this year’s AHA volunteer president and the theme of his presidential lecture: science's last mile. The hosts then break down the implications of the ZEUS and Lp(a) HORIZON trials, where therapies lowered biomarker targets without reducing cardiovascular events. The hosts consider why well-designed randomized trials remain the only reliable path to answers about outcomes. Next, they turn to a few of the more than 60 sessions featuring DCRI faculty: the RACE-CARS cardiac arrest trial, the RECOVER-AUTONOMIC trial in long COVID, the Test 2 Treat implementation study on LDL cholesterol testing, and a VESALIUS-CV cost-effectiveness analysis of evolocumab. The hosts also share the dark horse presentations that caught their eye, from renewed debate over blood pressure targets in diabetes to agentic AI in health systems. They then consider how closing the last mile for delivery can become the first mile for discovery. 

Related Headlines from this Episode

Share